Polyclonal Antibody to Glucocorticoid Receptor (GR)
| Code | Size | Price |
|---|
| PAB608Mu02-20ul | 20ul | £89.00 |
Quantity:
| PAB608Mu02-100ul | 100ul | £166.00 |
Quantity:
| PAB608Mu02-200ul | 200ul | £224.00 |
Quantity:
| PAB608Mu02-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GCCR; GCR; NR3C1; GRL; NR3-C1; Nuclear Receptor Subfamily 3, Group C, Member 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Immunogen:
RPB608Mu02-Recombinant Glucocorticoid Receptor (GR)
Item Name:
Glucocorticoid Receptor
Source:
Polyclonal antibody preparation
Subcategory:
Polyclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Nuclear Receptor Subfamily 3, Group C, Member 1 (NR3C1) | RPB608Mu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||